Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis
Metrics: PDF 826 views | HTML 1173 views | ?
Hui Luo1, Saisai Li1, Menghuang Zhao1, Bo Sheng1, Haiyan Zhu1 and Xueqiong Zhu1
1 Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Xueqiong Zhu, email:
Haiyan Zhu, email:
Keywords: prognostic, progesterone receptor, ovarian cancer, meta-analysis
Received: December 16, 2016 Accepted: February 28, 2017 Published: March 07, 2017
Objective: While a prognosis value of progesterone receptor (PR) in ovarian cancer has been reported in some publications, controversial data were presented by different reports. In order to address the disagreement of progesterone receptor in ovarian cancer survival, we conducted this meta-analysis.
Methods: Relevant articles on progesterone receptor and ovarian cancer prognosis were identified via a thorough search of PubMed, Embase and Cochrane Central. Hazard ratios (HR) and 95% confidence interval (CI) were extracted from studies on overall survival (OS) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS).
Result: A total of 28 eligible studies containing 5685 patients were collected for analysis. It was found that progesterone receptor positivity was significantly associated with favorable overall survival (OS) (HR = 0.86, 95% CI = 0.78 to 0.95, P = 0.002) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS) (HR = 0.75, 95% CI = 0.61 to 0.93, P = 0.008) of ovarian cancer patients. Subgroup analysis showed that progesterone receptor expression was associated with a favorable prognosis of unclassified ovarian cancer, European origin, and immunohistochemical detection method.
Conclusion: Progesterone receptor expression can be used as a favorable prognostic predictor in ovarian cancer managements.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.